| Literature DB >> 28275031 |
William G Wierda1, Andrew D Zelenetz2, Leo I Gordon3, Jeremy S Abramson4, Ranjana H Advani5, C Babis Andreadis6, Nancy Bartlett7, John C Byrd8, Paolo Caimi9, Luis E Fayad1, Richard I Fisher10, Martha J Glenn11, Thomas M Habermann12, Nancy Lee Harris4, Francisco Hernandez-Ilizaliturri13, Richard T Hoppe5, Steven M Horwitz2, Mark S Kaminski14, Christopher R Kelsey15, Youn H Kim5, Susan Krivacic16, Ann S LaCasce17, Michael G Martin18, Auayporn Nademanee19, Pierluigi Porcu8, Oliver Press20, Rachel Rabinovitch21, Nishitha Reddy22, Erin Reid23, Kenneth Roberts24, Ayman A Saad25, Erin D Snyder25, Lubomir Sokol26, Lode J Swinnen27, Julie M Vose28, Joachim Yahalom2, Mary A Dwyer29, Hema Sundar29.
Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.Entities:
Mesh：
Year: 2017 PMID： 28275031 DOI： 10.6004/jnccn.2017.0030
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908